Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Koi Peptides (operating under Koi Research Labs LLC) is a United States-based supplier of high-purity research peptides and multi-peptide blends intended strictly for laboratory and in vitro research use. Founded in 2022, the company emphasizes analytical transparency and quality control, characterizing its products using reverse-phase High-Performance Liquid Chromatography (HPLC) for purity, mass spectrometry for identity, and Limulus Amebocyte Lysate (LAL) assays for endotoxin screening. Koi Peptides provides lot-specific, third-party verified Certificates of Analysis (COAs) through a searchable public library. Its product catalog includes individual reference compounds such as BPC-157 and GHK-Cu, as well as multi-peptide formulations like the Glow and Klow peptide stacks.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Koi Peptides.